Comparative study of HMG-CoA reductase inhibitors on fibrinogen

Atherosclerosis

Volumn 155, Issue 2, 2001, Pages 463-466

  Rosenson, Robert S ^a   Tangney, Christine C ^a   Schaefer, Ernst J ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular risk; Fibrinogen; HMG CoA reductase inhibitor

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FIBRINOGEN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG RESPONSE; EVALUATION; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLING; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CORONARY DISEASE; CROSS-OVER STUDIES; FATTY ACIDS, MONOUNSATURATED; FEMALE; FIBRINOGEN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LOVASTATIN; MALE; MIDDLE AGED; PRAVASTATIN; PYRROLES; SIMVASTATIN;

EID: 0035089758     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00590-6     Document Type: Article

References (17)

1. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies
2. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
3. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men
4. Anti-atherothrombotic properties of statins: Implications for cardiovascular event reduction
5. Effects of lipids and lipoproteins on thrombosis and rheology
6. Effects of tourniquet technique, order of draw, and sample storage on plasma fibrinogen
7. Quick method to estimate fibrinogen by a functional clotting assay
8. Variability in plasma viscosity and fibrinogen measurements are an obstacle to cardiovascular risk assessment
9. Intraindividual variability of fibrinogen levels and cardiovascular risk profile
10. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men
11. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
12. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease
13. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
14. Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia
15. A population based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries
16. Blood rheology and outcome in one West of Scotland Coronary Prevention Study: Is the benefit of lipoprotein reduction partly due to lower viscosity?
17. Effects of statins on plasma fibrinogen